NASDAQ: IKNA - Ikena Oncology, Inc.

半年間の収益性: -23.12%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Ikena Oncology, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Ikena Oncology, Inc.

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas.

さらに詳しく
Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2021-03-26
ISIN US45175G1085
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://ikenaoncology.com
Цена ао 1.3
1日あたりの価格変動: 0% (1.33)
週ごとの価格変動: -2.92% (1.37)
月ごとの料金変更: -2.92% (1.37)
3ヶ月間の価格変動: -13.64% (1.54)
半年間の価格変動: -23.12% (1.73)
年間の価格変動: -6.34% (1.42)
3年間の価格推移: -79.66% (6.54)
年初からの価格変動: -18.9% (1.64)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 9.52 1
P/BV 0.6285 10
P/E 0 0
EV/EBITDA -0.8016 0
合計: 5.13

効率

名前 意味 学年
ROA, % -29.52 0
ROE, % -33.3 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.1275 10
合計: 9.8

成長の衝動

名前 意味 学年
収益性 Revenue, % -33.62 0
収益性 Ebitda, % 33.42 5
収益性 EPS, % -20.3 0
合計: 2
さらに詳しく

機関 音量 共有, %
Orbimed Advisors LLC. 9907945 20.53
Atlas Venture Life Science Advisors, LLC 5018178 10.4
BVF Inc. 4769164 9.88
FMR, LLC 4184293 8.67
Omega Fund Management, Llc 2249123 4.66
Blue Owl Capital Holdings LP 1953616 4.05
Blackrock Inc. 1858156 3.85
Vanguard Group Inc 1524848 3.16
Verition Fund Management, LLC 1322397 2.74
Artal Group S.A. 999513 2.07

ETF共有, %年間の利益率, %配当金, %
iShares Micro-Cap ETF 0.0129 17.09 1.54048
0.0117.091.54



スーパーバイザー 役職 支払い 生年
Dr. Mark Manfredi Ph.D. President, CEO & Director 810.69k 1971 (54 年)
Dr. Jotin Marango M.D., Ph.D. CFO & Head of Corporate Development 577.12k 1979 (46 年)
Mr. Bob Lally Senior Vice President of Finance & Operations N/A
Mr. Jeffrey Ecsedy Ph.D. Chief Development Officer N/A 1970 (55 年)
Mr. David Damphousse M.S. Senior Vice President of Clinical Development Operations N/A
Mr. Valdas Jurkauskas Ph.D. Senior Vice President of Technical Operations N/A
Dr. Caroline Germa M.D., Ph.D. Chief Medical Officer N/A 1972 (53 年)
Ms. Rebecca Cohen Vice President of Investor Relations, Corporate Strategy & Communication

住所: United States, Boston. MA, 645 Summer Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://ikenaoncology.com